This document provides an overview of non-clinical (pre-clinical) drug development. It discusses key terminology used in pre-clinical development like CTD, NOAEL, IND, NCE, NDA. It explains that pre-clinical development spans the gap between discovery and first-in-human clinical trials, with the goal of identifying the safest lead candidate and building a scientific foundation for clinical trials. The document outlines the main components of pre-clinical development, including pharmacology studies, safety pharmacology, PK/ADME studies, toxicology studies, and starting dose selection. It notes that pre-clinical studies must adhere to ICH GLP guidelines. The CTD pyramid is also discussed as the common